Illustration: Gabriella Turrisi/Axios
Evommune, a Palo Alto-based biotech focused on autoimmune diseases, raised $150 million in its IPO at $16 per share.
The big picture: Evommune is at least the third biotech company to test public markets after a half-year drought.
